Universal reference book for medicines
Product name: MACMIROR COMPLEX (MACMIROR COMPLEX)

Active substance: nifuratel, nystatin

Type: The drug with antibacterial, antiprotozoal and antifungal action for topical application in gynecology

Manufacturer: POLICHEM SrL (Italy) manufactured by DOPPEL FARMACEUTICI (Italy)
Composition, form of production and packaging
Suppositories vaginal
soft gelatinous, ovoid, yellow in color with a brown tinge;
the contents of suppositories - an oily suspension of yellow color.
1 supp.

nifuratel 500 mg

nystatin 200 thousand IU

Excipients: dimethylpolysiloxane AK 1000 (dimethicone) 960.0 mg.

Sheath composition: gelatin 351.0 mg, glycerol (glycerol) 171.0 mg, ethylparahydroxybenzoate sodium 1.8 mg, sodium propyl parahydroxybenzoate 1.0 mg, titanium dioxide 0.4 mg, iron oxide yellow 2.4 mg

8 pcs.
- blisters (1) - packs of cardboard.
12 pcs.
- blisters (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2016.

PHARMACHOLOGIC EFFECT

Antimicrobial preparation for topical application.
Has antiprotozoal, antifungal and antibacterial action.
Nifuratel - a derivative of nitrofuran - is highly active against a number of bacteria, fungi and protozoa (including Trichomonas vaginalis).

Nystatin is an antifungal antibiotic of the polyene group.
By binding to sterols in the cell membrane of fungi, it breaks its permeability, which leads to cell death.Highly active against Candida albicans.
The combination of nifuratel and nystatin allows to achieve more pronounced antifungal action and significantly expand the spectrum of antimicrobial action.

High efficacy and low toxicity of the components of the drug cause a wide range of its clinical applications in the treatment of mixed etiologies of vaginitis, in particular, the use for the prevention of fungal infections caused by specific treatment of trichomoniasis.

Macmirror The complex does not violate the physiological flora, which allows to avoid the development of dysbacteriosis and quickly restore the normocenosis of the vagina.

PHARMACOKINETICS

The conducted studies confirm that, when administered vaginally in animals (rabbits and dogs) with repeated administration of a daily dose, which is 30 times higher than the therapeutic dose, the substances that make up the drug have no systemic effect.

The conducted studies of the pharmacokinetics of the drug in humans also confirm that, with intravaginal application, the drug is not practically absorbed from the surface of the vaginal mucosa and does not have a systemic effect.

The concentration of nifuratel in the blood plasma is below the limit of quantitation.
The maximum concentration (C max ) is 4.54 ng / ml; Time to reach the maximum concentration (T max ) 8.0 h; the integral area under the pharmacokinetic curve "concentration-time" (AUC) 10.27 ng ml- 1 h.
Nystatin is not absorbed through the skin and mucous membranes during topical application.

INDICATIONS

- vulvovaginal infections caused by drug-susceptible pathogens: incl.
bacterial vaginitis, vaginal trichomoniasis; Vaginitis caused by fungi of the genus Candida, mixed vaginitis.
DOSING MODE

Intravaginal: 1 vaginal suppository is administered daily at night before bedtime for 8 days or as recommended by the doctor.
If necessary, treatment can be repeated after menstruation.
To achieve maximum effect, the suppository is injected deep into the vagina.

SIDE EFFECT

Allergic reactions are possible in the form of skin rashes or itching.
With the development of allergic reactions, the drug should be discontinued.
CONTRAINDICATIONS

- hypersensitivity to nifuratel, nystatin or any auxiliary substance of the drug;

- childhood.

PREGNANCY AND LACTATION

The use of the drug during pregnancy is possible if the potential benefit to the mother exceeds the risk to the fetus or child.

Possible application in the period of breastfeeding, tk.
the drug is almost not absorbed through the mucous membranes, so it does not penetrate breast milk.
SPECIAL INSTRUCTIONS

It is necessary to conduct simultaneous treatment of the sexual partner because of the danger of re-infection.
During the treatment with the drug, sexual intercourse should be avoided.
Suppositories are not used for treatment in childhood, when it is necessary to use the drug in this category of patients, it is recommended to apply the preparation Macmiore Complex in the form of a cream vaginal cream complete with an applicator (graduated syringe).
The presence of a special nozzle allows you to enter the cream without damaging the hymen.
Influence on ability to drive vehicles, mechanisms

The use of the drug does not affect the ability to drive vehicles and other activities that require increased attention.

OVERDOSE

No cases of drug overdose have been reported.

DRUG INTERACTION

There is no clinically significant interaction of the McMiore Complex cream with other drugs.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

In a dry place at a temperature of no higher than 25 ° C.
Keep out of the reach of children! Shelf life - 3 years. Do not use after expiry date.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!